Ipsen is seeking partnerships in neuromuscular and neurodegenerative disorders
Ipsen business development
Ipsen is a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000.
The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The Group complements implementation of its internal Research and Development programme by entering into partnership agreements with university teams and pharmaceutical and biotechnology companies. These partnerships help the Group to gain access to cutting-edge technologies in complex areas of expertise.
The Group is constantly looking to forge high-quality, complementary and longlasting marketing and Research and Development partnerships.
The Group's research programmes in neuromuscular disorders mainly focus on the identification of new botulinum toxin formulations. In neurodegenerative conditions, Ipsen has synthesised several innovative classes of chimeric compounds, i.e. compounds capable of performing several pharmacological activities simultaneously and used to protect mitochondria (intracellular organelles responsible for the production of energy) in connection with neurodegenerative conditions, such as Parkinson's and Huntington's disease.